News

Andrew G. Lee, MD, and Drew Carey, MD, return for this latest episode of the NeuroOp Guru to discuss whether a dead nerve can swell, focusing on the condition of papilledema caused by elevated intracranial pressure.

The iDose platform is designed to address ubiquitous patient non-adherence and chronic side effects associated with topical medications by providing 24/7 release of medication.

RayTrace has been utilized globally by surgeons since 2008.

The transferrin vectorised therapy is being investigated for use in patients with dry age-related macular degeneration and geographic atrophy

Autonomous, AI-based screening consistently resulted in more patients screened with greater cost savings, investigators said

They report a case of endophthalmitis and undertook a literature review to identify previous infections with this pathogen.

The phase 1 clinical trial is a multicenter, open-label, dose-escalation study to assess drug safety via intravitreal injection in 3 cohorts.

A case report highlights the pathogen’s potential to cause severe, devastating ocular infections, despite aggressive treatment

Cost among other factors may deter patients from screening, especially in rural and low-resource settings.

The company's lead product candidate Duravyu (vorolanib intravitreal insert), f/k/a EYP-1901, is anticipating topline data from several clinical trials in 2026.

The transferrin vectorised therapy is being investigated for use in patients with dry age-related macular degeneration and geographic atrophy

The trial evaluated ONS-5010 in wet age-related macular degeneration patients, and the company plans to resubmit a Biologics License Application in the first quarter of 2025.

InflammX’s pipeline includes an orally dosed therapeutic candidate targeting intermediate age-related macular degeneration.

Study sees a positive association between the dietary inflammatory index (DII) and non-refractive visual impairment among US populations

The company, which has European headquarters in Basel, Switzerland, plans to use the funds for a non-interventional, observational study and a first-in-human clinical trial

Advances in biometric technology and IOL calculation formulas have enabled refractive accuracy of cataract and clear lens exchange (CLE) surgery, but IOL power selection remains challenging in some cases. I have found that the ZEISS IOL Power Calculation Service (IPCS) is a valuable asset to help me in these uncertain situations.

The funding will support activities like formal pharmacology and toxicology testing.

The new funding will allow the company to complete its ongoing Phase 2 trial of proprietary nanomedicine, migaldendranib, in patients with wet AMD and DME

Dr. Frenkel highlights a comprehensive program that covers the latest breakthroughs in glaucoma and cataract surgery to in-depth discussions on AI, retinal treatments, and new drug-delivery platforms, all set against the backdrop of Snowmass, Colorado.

The laser integrates into the Corneal Refractive Workflow alongside the Visumax 800 and SMILE pro software

The launch follows a CE Mark received late last year.

The objective of this trial was to evaluate safety and tolerability and identify dose level for further evaluation.

The company will prioritize its cash in funding its ongoing Phase 1/2 PRISM clinical trial and Phase 3 4FRONT program.

With this addition, Zeiss completes the Corneal Refractive Workflow, which already includes Visumax 800 and SMILE pro.

Previously, Teva was established as the European commercialisation partner of FYB201, Formycon's biosimilar to ranibizumab (Lucentis).